Albuked Market Report 2026

Albuked Market Overview

• The Albuked market growth in the historic period has been driven by clinical use of albumin in shock management, reliance on plasma derived albumin • Market expansion is supported by demand for safer non plasma products, increasing burn and trauma cases • Growth Driver: Rising Liver Disorders Driving Growth In Albuked Market • Market Trend: Advancement In Human Albumin Injection Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Albuked Market?

Albuked is a recombinant human albumin-based therapeutic protein used primarily in the treatment of hypoalbuminemia, a condition where albumin levels are abnormally low in the blood. It is produced through genetic engineering techniques and is used in various medical conditions, including liver cirrhosis, nephrotic syndrome, and burns. Albuked works by replenishing the albumin in the bloodstream, helping to maintain fluid balance, improve circulation, and prevent complications from protein deficiencies. As a synthetic product, it offers an alternative to plasma-derived albumin. It is typically administered intravenously under medical supervision. The main formulation types of albuked are albuked 5%, albuked 25%, plasbumin-5, and plasbumin-25. Albuked 5% is a formulation of human serum albumin designed for therapeutic use in managing various medical conditions such as hypovolemia and hypoalbuminemia. The indications are hypovolemic shock, hypoproteinemia, acute respiratory distress syndrome (ARDS), cardiopulmonary bypass, and acute liver failure, and the packaging size includes 50 ml, 250 ml, and 500 ml. Various distribution channels include hospitals and clinics and retail and specialty pharmacies, and they are used by different end users, such as adult patients and geriatric patients.

What Is The Albuked Market Growth Forecast?

The growth in the forecast period can be attributed to demand for safer non plasma products, increasing burn and trauma cases, expansion of recombinant protein manufacturing, rising ICU admissions, regulatory support for synthetic proteins. Major trends in the forecast period include growing adoption of recombinant albumin, shift away from plasma derived albumin, rising use in critical care settings, increasing preference for synthetic therapeutics, expansion of intravenous protein therapies.

Global Albuked Market Segmentation

1) By Formulation: Albuked 5%, Albuked 25%, Plasbumin-5, Plasbumin-25 2) By Indication: Hypovolemic Shock, Hypoproteinemia, Acute Respiratory Distress Syndrome (ARDS), Cardiopulmonary Bypass, Acute Liver Failure 3) By Packaging Size: 50 mL, 250 mL, 500 mL 4) By Distribution Channel: Hospitals And Clinics, Retail And Specialty Pharmacies 5) By End User: Adult Patients, Geriatric Patients

What Is The Driver Of The Albuked Market?

The rising incidence of liver disorders is expected to propel the growth of the albuked market going forward. Liver disorders encompass various conditions affecting liver function, including hepatitis, cirrhosis, fatty liver disease, and autoimmune diseases. Increasing liver disorders are due to excessive alcohol consumption, obesity, viral infections, toxin exposure, and genetic predispositions affecting liver health. Albuked is used in liver disorders, particularly for managing acute liver failure. It helps support the colloid osmotic pressure of plasma and binds excess bilirubin in patients with rapid liver function loss, potentially preventing complications such as coma​. For instance, in September 2023, according to the American Liver Foundation, a US-based non-profit organization, over 100 million people in the U.S. are affected by some form of liver disease. Among them, 4.5 million adults (1.8%) have received a formal diagnosis and it is estimated that 80-100 million adults in the U.S. have fatty liver disease, with many remaining unaware of their condition. Furthermore, in August 2023, according to the Journal of Hepatology, a Switzerland-based peer-reviewed monthly journal, liver disease is responsible for over 2 million deaths each year, which accounts for about 4% of all deaths worldwide. This means that 1 in every 25 deaths is related to liver issues. Notably, one-third of these deaths occur in women. Among the various liver diseases, liver cancer alone causes between 600,000 and 900,000 deaths annually. Therefore, the rising incidence of liver disorders is driving the Albuked industry.

Key Players In The Global Albuked Market

Major companies operating in the albuked market are Kedrion Biopharma Inc.

Global Albuked Market Trends and Insights

The key trend in the Albuked market is focusing on the development of advanced products such as human albumin injection therapy to provide treatment options for critical medical conditions. Human albumin injection therapy refers to the use of human serum albumin (HSA), a protein derived from human plasma, for various medical treatments. This therapy is primarily utilized in clinical settings to manage conditions such as hypoalbuminemia, liver cirrhosis, trauma, and burns, and during surgeries where fluid resuscitation is necessary. For instance, in July 2023, Grifols S.A., a Spain-based manufacturer of plasma-derived medicines, announced the phase 3 completion of PRECIOSA to determine the potential of long-term albumin-based treatment with Grifols S.A.’s Albutein. The clinical study aims to increase the survival time of patients suffering from decompensated cirrhosis and ascites until a suitable transplant is available.

What Are Latest Mergers And Acquisitions In The Albuked Market?

In June 2023, Kedrion Biopharma, a US-based biopharmaceutical company, partnered with BPL (Bio Products Laboratory) to expand the availability of plasma-derived therapies in China. The collaboration between Kedrion Biopharma and BPL aims to expand the availability of plasma-derived therapies, specifically human albumin, in the Chinese market. Bio Products Laboratory (BPL) is a UK-based pharmaceutical company that manufactures and supplies plasma-derived products for healthcare professionals and patients.

Regional Insights

North America was the largest region in the albuked market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Albuked Market?

The albuked market consists of sales of Albuminar-5, Albuminar-25, and Buminate. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Albuked Market Report 2026?

The albuked market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the albuked industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.